Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PAVM vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–3 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: PAVM 0 – 6 DCTH Matrix Metrics: PAVM 3 – 6 DCTH

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over PAVmed Inc. (PAVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PAVM carries a Unified Composite Score of 45.6/100 (HOLD) at $1.65 (N/M Forward P/E, -23842.0% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While PAVM currently prints a higher short-term Unified Composite Score (45.6/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -23842.0% operating margin) and revenue trajectory (+70.7% vs. +450.0% YoY).
  • Technical & Structure Timing Caution: PAVM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.6); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PAVM vs DCTH
PAVM NASDAQ
PAVmed Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.65
+0.92% 1D
Market Cap $12.2M
TTM Revenue $112,000
Forward P/E N/M
Beta / 30D Vol 0.47β · 117% Vol
Unified Composite Score
45.6 / 100 HOLD
Tech 48.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.4%), weak momentum, RSI 40
RSI-14: 39.6 · SMA20: $1.85 · SMA50: $2.80
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (PAVM 0 – 6 DCTH)

Columns: Metric · PAVM · DCTH
1. Valuation Multiples DCTH
Forward P/E N/M N/M
Trailing P/E N/M 133.6x
PEG Ratio N/M 1.60x
EV / Revenue N/M 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) +450.0% +70.7%
Earnings Growth (YoY) +0.0% +750.0%
TTM Revenue (USD) $112,000 $110M
Market Cap $12.2M $743.8M
3. Profitability & Quality DCTH
Gross Margin N/A 87.6%
Operating Margin -23842.0% 5.2%
Net Profit Margin 0.0% 6.0%
Return on Equity (ROE) -64.8% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) -$6.3M $20M
Cash Flow Margin N/A 18.3%
Net Cash / Leverage $11M Net Debt (0.43x D/E) $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile N/A (N/A) 109.3% (43rd %ile)
Put/Call OI Skew N/A 0.11x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity N/A 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PAVM (3) vs DCTH (6)
Institutional Metric PAVM DCTH Criterion Row Edge
Market Capitalization
Scale
$12.2M $743.8M Larger Scale DCTH
Trailing P/E Ratio
Valuation
N/M 133.6x Lower Multiple DCTH
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+450.0% +70.7% Higher Growth PAVM
Operating Margin (TTM)
Profitability
-23842.0% 5.2% Higher Margin DCTH
Net Profit Margin
Profitability
0.0% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
-64.8% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
5% ($0–$28) 80% ($8–$23) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
0.47β · 117% Vol 1.63β · 131% Vol Lower Realized Risk PAVM
Unified Institutional Score
Composite Signal
45.6 / 100 (HOLD) 35.9 / 100 (SELL) Higher Composite PAVM
Trailing 12M Revenue (USD)
Operating Scale
$112,000 $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.3M ($11M Net Debt (0.43x D/E)) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +71.51 pp
PAVM: -31.74% · DCTH: +39.77%
3M Horizon DCTH +84.22 pp
PAVM: -67.49% · DCTH: +16.73%
6M Horizon DCTH +150.97 pp
PAVM: -73.51% · DCTH: +77.46%
1Y Horizon PAVM +236.51 pp
PAVM: +365.08% · DCTH: +128.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PAVM Revenue DCTH Revenue PAVM Op. Margin DCTH Op. Margin Margin Leader
FY2013 N/A $0M N/A -4179.6% DCTH
FY2014 N/A $0M N/A -1805.8% DCTH
FY2015 N/A $0M N/A -870.6% DCTH
FY2021 $0M $0M -10878.6% -690.0% DCTH
FY2022 $0M $0M -24161.0% -1245.1% DCTH
FY2023 $0M $0M -2805.7% -1849.0% DCTH
FY2024 $0M $40M -1485.4% -33.4% DCTH
FY2025 $0M $90M -30712.7% 0.8% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PAVM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PAVM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PAVM Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.2M market capitalization and -23842.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ PAVM vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over PAVmed Inc. (PAVM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PAVM carries a Unified Composite Score of 45.6/100 (HOLD) at $1.65 (N/M Forward P/E, -23842.0% operating margin), whereas DCTH carries 35.9/100 (SELL) at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While PAVM currently prints a higher short-term Unified Composite Score (45.6/100 HOLD vs. DCTH 35.9/100 SELL), DCTH captures the overall institutional head-to-head verdict (6–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -23842.0% operating margin) and revenue trajectory (+70.7% vs. +450.0% YoY). Technical & Structure Timing Caution: PAVM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.6); meanwhile DCTH trades in a Neutral technical trend (BREAKOUT options phase, RSI 68.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: PAVM posts +450.0% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -23842.0% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2013 to FY2025), PAVM cumulative revenue shifted N/A while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, PAVM deploys N/A (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

DCTH screens cheaper on headline valuation multiples. PAVM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PAVM (-64.8% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, PAVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.47β · 117% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.